1. Home
  2. TBPH vs ALRS Comparison

TBPH vs ALRS Comparison

Compare TBPH & ALRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • ALRS
  • Stock Information
  • Founded
  • TBPH 2013
  • ALRS 1879
  • Country
  • TBPH United States
  • ALRS United States
  • Employees
  • TBPH N/A
  • ALRS N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • ALRS Major Banks
  • Sector
  • TBPH Health Care
  • ALRS Finance
  • Exchange
  • TBPH Nasdaq
  • ALRS Nasdaq
  • Market Cap
  • TBPH 464.5M
  • ALRS 468.2M
  • IPO Year
  • TBPH N/A
  • ALRS 2019
  • Fundamental
  • Price
  • TBPH $10.67
  • ALRS $21.98
  • Analyst Decision
  • TBPH Buy
  • ALRS Hold
  • Analyst Count
  • TBPH 4
  • ALRS 5
  • Target Price
  • TBPH $14.50
  • ALRS $23.20
  • AVG Volume (30 Days)
  • TBPH 305.1K
  • ALRS 62.2K
  • Earning Date
  • TBPH 08-04-2025
  • ALRS 07-23-2025
  • Dividend Yield
  • TBPH N/A
  • ALRS 3.83%
  • EPS Growth
  • TBPH N/A
  • ALRS 118.02
  • EPS
  • TBPH N/A
  • ALRS 1.08
  • Revenue
  • TBPH $65,266,000.00
  • ALRS $224,218,000.00
  • Revenue This Year
  • TBPH $43.18
  • ALRS $40.50
  • Revenue Next Year
  • TBPH N/A
  • ALRS $3.54
  • P/E Ratio
  • TBPH N/A
  • ALRS $20.26
  • Revenue Growth
  • TBPH 6.11
  • ALRS 35.73
  • 52 Week Low
  • TBPH $7.44
  • ALRS $15.78
  • 52 Week High
  • TBPH $11.82
  • ALRS $24.41
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 57.88
  • ALRS 63.94
  • Support Level
  • TBPH $10.44
  • ALRS $20.83
  • Resistance Level
  • TBPH $11.00
  • ALRS $21.88
  • Average True Range (ATR)
  • TBPH 0.30
  • ALRS 0.41
  • MACD
  • TBPH -0.05
  • ALRS -0.02
  • Stochastic Oscillator
  • TBPH 23.15
  • ALRS 91.51

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About ALRS Alerus Financial Corporation

Alerus Financial Corp is a financial holding company registered in the United States. The company operates in four segments: Banking, Retirement & Benefit Services, Wealth Management, and Mortgage. It provides various banking services such as checking, debit cards, savings, current deposits, loans and advances, online banking, mobile banking, private banking, payment solutions, and other business products. Additionally, the company provides mortgage loans, retirement planning solutions, individual retirement accounts, retirement plan advisory services as well as wealth management services, including financial & estate planning, trust, and fiduciary services. The company's revenue mainly consists of interest income, commission, management fees, and other income.

Share on Social Networks: